24.91 USD
↘ 1.13 (4.34%)AT CLOSE (11:59 AM EDT)
Ultragenyx Pharmaceutical Inc.
RARENASDAQ • USD
25.57
↗ 0.66 (2.65%)
POST MARKET (AS OF 07:49 PM EDT)
Post Market
AS OF 07:49 PM EDT
25.57
↗ 0.66 (2.65%)
Market: CLOSED
Ultragenyx Pharmaceutical Inc. (RARE) trades at $24.91 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (258.0%) and a bullish Golden Cross on the moving averages. On valuation, RARE trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jul 31, 2026.
Open?$25.95
High?$26.08
Low?$24.60
Prev. Close?$26.04
Volume?1.5M
Avg. Volume?2.7M
VWAP?$24.95
Rel. Volume?0.57x
Bid / Ask
Bid?$24.05 × 100
Ask?$28.00 × 100
Spread?$3.95
Midpoint?$26.03
Valuation & Ratios
Market Cap?2.5B
Shares Out?98.5M
Float?93.4M
Float %?94.9%
P/E Ratio?N/A
P/B Ratio?-10.40
EPS?-$6.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Employees
1.4K
Market Cap
2.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-01-31
Address
60 LEVERONI COURT
NOVATO, CA 94949
Phone: 415-483-8800
NOVATO, CA 94949
Phone: 415-483-8800
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?64
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.73Distress
Confidence?61%Moderate
Short InterestHigh
Short % of Float?14.38%High
Short Interest?13.4M
Days to Cover?6.9
Free Float93.4M
Avg Daily Volume1.9M
Settlement Date2026-07-15
Financial Health
Current Ratio?2.02Strong
Quick Ratio?1.85Adequate
Cash Ratio?0.54Adequate
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?-10.40CHEAP▾
S&P97
P/S?3.66FAIR▾
Peers100
S&P42
P/FCF?N/A▾
EV/EBITDA?-4.3CHEAP▾
S&P97
EV/Sales?3.40FAIR▾
Peers100
S&P55
Returns & Efficiency
ROE?258.0%STRONG▾
Peers50
S&P97
ROA?-47.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-502201000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day